// App-Quantinova.ai

Sa2049 : One Third of Patients Treated With Adalimumab or Infliximab for Crohn's Disease or Ulcerative Colitis Permanently Dose-Escalate Due to Loss of Response

Researchers

Presenter

  • Pam Osatiuk

Principal Investigators

  • Karen Wong

  • Karen I. Kroeker

  • Levinus A. Dieleman

  • Richard N. Fedorak

Medical Centers

  • Hepatology, University of Alberta, Edmonton, Alberta, Canada

  • BioAdvance, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Infliximab

  • Regain

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved